These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27172829)

  • 1. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.
    Bang J; Lobach IV; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Gold M; Morimoto BH; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():41-48. PubMed ID: 27172829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
    Tsai RM; Lobach I; Bang J; Whitwell JL; Senjem ML; Jack CR; Rosen H; Miller B; Boxer AL;
    Parkinsonism Relat Disord; 2016 Jul; 28():29-35. PubMed ID: 27132501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Amantadine Usage, Gait, and Cognition in PSP: A
    Dale ML; Brumbach BH; Boxer AL; Hiller AL
    Front Neurol; 2020; 11():606925. PubMed ID: 33408688
    [No Abstract]   [Full Text] [Related]  

  • 4. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.
    Höglinger GU; Schöpe J; Stamelou M; Kassubek J; Del Ser T; Boxer AL; Wagenpfeil S; Huppertz HJ; ; ;
    Mov Disord; 2017 Jun; 32(6):842-852. PubMed ID: 28436538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
    Hewer S; Varley S; Boxer AL; Paul E; Williams DR;
    Mov Disord; 2016 Oct; 31(10):1574-1577. PubMed ID: 27324431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammation predicts disease progression in progressive supranuclear palsy.
    Malpetti M; Passamonti L; Jones PS; Street D; Rittman T; Fryer TD; Hong YT; Vàsquez Rodriguez P; Bevan-Jones WR; Aigbirhio FI; O'Brien JT; Rowe JB
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):769-775. PubMed ID: 33731439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
    Rojas JC; Bang J; Lobach IV; Tsai RM; Rabinovici GD; Miller BL; Boxer AL;
    Neurology; 2018 Jan; 90(4):e273-e281. PubMed ID: 29282336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy.
    Abate F; Russo M; Ricciardi C; Tepedino MF; Romano M; Erro R; Pellecchia MT; Amboni M; Barone P; Picillo M
    Parkinsonism Relat Disord; 2023 Apr; 109():105345. PubMed ID: 36868037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy.
    Duff K; Randolph C; Boxer AL
    Clin Neuropsychol; 2020 Apr; 34(3):529-540. PubMed ID: 31559910
    [No Abstract]   [Full Text] [Related]  

  • 10. Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study.
    Quattrone A; Morelli M; Quattrone A; Vescio B; Nigro S; Arabia G; Nisticò R; Novellino F; Salsone M; Arcuri P; Luca A; Mazzuca A; Alessio C; Rocca F; Caracciolo M
    Parkinsonism Relat Disord; 2020 Mar; 72():1-6. PubMed ID: 32036297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.
    Wills AM; Pantelyat A; Espay A; Chan J; Litvan I; Xie T; Dale ML; Gunzler SA; Tartaglia MC; Fox SH; Rodriguez-Porcel F; Sharma M; Lang AE; Boxer AL; ; Golbe LI
    Mov Disord; 2022 Jun; 37(6):1265-1271. PubMed ID: 35363932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
    Boxer AL; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Golbe LI; Williams DR; Corvol JC; Ludolph A; Burn D; Lorenzl S; Litvan I; Roberson ED; Höglinger GU; Koestler M; Jack CR; Van Deerlin V; Randolph C; Lobach IV; Heuer HW; Gozes I; Parker L; Whitaker S; Hirman J; Stewart AJ; Gold M; Morimoto BH;
    Lancet Neurol; 2014 Jul; 13(7):676-85. PubMed ID: 24873720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of decline in progressive supranuclear palsy.
    Litvan I; Kong M
    Mov Disord; 2014 Apr; 29(4):463-8. PubMed ID: 24615741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.
    Duff K; McDermott D; Luong D; Randolph C; Boxer AL
    J Clin Exp Neuropsychol; 2019 Jul; 41(5):469-475. PubMed ID: 30712468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a cognitive composite for measuring change in progressive supranuclear palsy.
    Jaeger J; Yang L; Li Y; Castrillo-Viguera C; Haeberlein SB; Dam T; O'Gorman J
    Parkinsonism Relat Disord; 2021 Nov; 92():94-100. PubMed ID: 34736158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
    Gozes I; Shapira G; Lobyntseva A; Shomron N
    Transl Psychiatry; 2023 Oct; 13(1):319. PubMed ID: 37845254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical rating scale for progressive supranuclear palsy.
    Golbe LI; Ohman-Strickland PA
    Brain; 2007 Jun; 130(Pt 6):1552-65. PubMed ID: 17405767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy.
    Weng R; Wei X; Yu B; Zhu S; Yang X; Xie F; Zhang M; Jiang Y; Feng ZP; Sun HS; Xia Y; Jin K; Chan P; Wang Q; Gao X
    Parkinsonism Relat Disord; 2018 Jul; 52():37-42. PubMed ID: 29574085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
    VandeVrede L; Dale ML; Fields S; Frank M; Hare E; Heuer HW; Keith K; Koestler M; Ljubenkov PA; McDermott D; Ohanesian N; Richards J; Rojas JC; Thijssen EH; Walsh C; Wang P; Wolf A; Quinn JF; Tsai R; Boxer AL
    Mov Disord Clin Pract; 2020 May; 7(4):440-447. PubMed ID: 32373661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome.
    Xie T; Wills AM; Liao C; Dale ML; Ramsden DB; Padmanaban M; Abou Chaar W; Pantelyat A; Golbe LI
    Mov Disord; 2023 Feb; 38(2):304-312. PubMed ID: 36573662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.